Advicenne announces the results of its capital increase with preferential subscription rights finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
02.10.2023 - Regulatory News: This press release must not be distributed directly or indirectly in the United States, Canada, Australia, or Japan. Advicenne (Euronext Growth - FR0013296746 - ALDVI), a pharmaceutical company specializing in the development and .
Advicenne Announces Its Participation in Several Scientific Conferences and the Presentation of Updated Clinical Results About ADV7103 finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Capital increase with pre-emptive subscription rights ("PSR") for an initial amount of €6.0 million, which may be increased to €6.9 million if the Extension Clause is fully exercised.Subscription price: €2.41 per share, i.e. a 27.4% discount on the face valueSubscription ratio: 1 new share per 4 existing sharesSubsc.
51% increase in Sibnayal® gross sales to €0.96 millionSignificant reduction in operating losses to €2.9 million (vs. €4.4 million in H1 2022)€0.9 million improvement in cash flow from operationsCash position of €3.42 millionCompletion of European marketing coverage for Sibnayal®Launch of a capital increase with pref.